Bhargava, Maneesh
Viken, K. J.
Barkes, B.
Griffin, T. J.
Gillespie, M.
Jagtap, P. D.
Sajulga, R.
Peterson, E. J.
Dincer, H. E.
Li, L.
Restrepo, C. I.
O’Connor, B. P.
Fingerlin, T. E.
Perlman, D. M.
Maier, L. A.
Funding for this research was provided by:
National Cancer Institute (U24CA199347)
National Heart, Lung, and Blood Institute (R01ES023826)
Article History
Received: 22 January 2020
Accepted: 17 June 2020
First Online: 6 August 2020
Competing interests
: CI Restrepo: Dr Restrepo has funding from Mallinckrodt Pharmaceuticals for a randomized double-blind placebo-controlled trial that is not relevant to this manuscript. No other financial conflict of interests to disclose. Maier LA: Dr Maier has funding from Mallinckrodt Pharmaceuticals for a randomized double-blind placebo-controlled trial that is not relevant to this manuscript. No other financial conflict of interests to disclose. Maneesh Bhargava: No conflict of interest. KJ Viken: No conflict of interest. B Barkes: No conflict of interest. TJ Griffin: No conflict of interest. M Gillespie: No conflict of interest. PD Jagtap: No conflict of interest. R Sajulga: No conflict of interest. EJPeterson: No conflict of interest. HE Dincer: No conflict of interest. L Li: No conflict of interest. BP O’Conno: No conflict of interest. TE: Fingerlin: No conflict of interest. DM Perlman: No conflict of interest.